

***Amendments to the Claims***

The listing of claims will replace all prior versions, and listings of claims in the application.

Claims 1-9 (cancelled).

Claim 10. (currently amended) A method of ~~preventing~~ inhibiting the occurrence of portal venous invasion, comprising administering to a patient in need thereof an effective dose of a medicine containing menatetrenone as an active ingredient thereof.

Claim 11. (currently amended) A method of inhibiting recurrence of hepatocellular carcinoma, comprising administering to a patient who has suffered from said carcinoma an effective dose of a medicine containing menatetrenone as an active ingredient thereof, wherein said effective dose is administered after treatment of the hepatocellular carcinoma has occurred.

Claims 12-15 (cancelled).

Claim 16 (new) The method of claim 10, wherein said administering to said patient occurs after treatment of said patient for hepatocellular carcinoma.

Claim 17 (new) The method of any one of claims 10, 11, or 16, wherein said effective dose of said medicine containing menatetrenone comprises the administration of generally 10 to 200 mg of menatetrenone per day to said patient.

Claim 18 (new) The method of claim 17, wherein said effective dose of a medicine containing menatetrenone comprises the administration of generally 30 to 135 mg of menatetrenone per day to said patient.

Claim 19 (new) The method of claim 18, wherein said effective dose of a medicine containing menatetrenone comprises the administration of 45 mg of menatetrenone per day to said patient.